This page contains exclusive content for the member of the following sections: TTS, CTS, IPITA, ISODP, IXA, ITA, TID, IHCTAS, IPTA. Log in to view.
Presenter: Wajahat Mehal, Andrew Posselt, ,
Authors: Wajahat Mehal, Andrew Posselt, Annmarie Huysman Liapakis
Dr. Mehal will speak on implementation of multidisciplinary care model - pharmacologic weight loss therapy in advanced liver disease and special considerations for the sarcopenic obese patient.
Dr. Posselt will speak on bariatric surgery: approach and special considerations in advanced liver disease.
Wajahat Mehal's Biography:
Dr. Mehal obtained his medical education at the University of Oxford England and completed his residency and GI fellowship at Yale University. He has been on faculty since 2001 and started the Fatty Liver Disease Program. He also leads a basic science research programs which examines the role of pattern recognition receptors and metabolic pathways in NASH. His work is funded by NIH grants and industry collaborations.
Andrew Posselt's Biography:
Dr. Andrew Posselt is an attending general and multi-organ transplant surgeon at UCSF and Director of the Pancreatic Islet Transplant Program. He specializes in adult and pediatric kidney, liver and pancreas transplantation as well as laparoscopic and open bariatric surgery. In addition to caring for patients, he conducts research on pancreatic islet transplantation, mechanisms of allograft rejection and tolerance, and the metabolic and biochemical consequences of bariatric surgery.
Dr. Posselt is a professor-in-residence in surgery at UCSF, where he supervises residents and fellows in transplant services and general surgery. He earned medical and doctorate degrees in immunology from the University of Pennsylvania and completed an internal medicine residency, general surgery residency and transplant fellowship at UCSF, before joining the staff in 2003.
By viewing the material on this site you understand and accept that: